Precision Medicine

Tumor genomic alterations appeared to differ among Black, white and Asian men with prostate cancer, according to results of a study published in The New England Journal of Medicine.

Patients with acute myeloid leukemia who opted for biomarker-based treatment achieved better outcomes than those who opted for standard chemotherapy, according to results of the Beat AML Master Clinical Trial published in Nature Medicine.

Though contending the care currently provided to patients is “poor,” a speaker at ASN Kidney Week said society is at a “uniquely positive sweet-spot” in which vascular access care, as well as kidney care as a whole, can be transformed.

Susan G. Komen selected two breast cancer researchers to receive Brinker Awards, the nonprofit organization’s highest scientific honor.

Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced colorectal cancer, substantial gaps in testing remain among certain patient groups, according to study results.

Stephen Gruber, MD, PhD, MPH, has been appointed director of City of Hope’s newly founded Center for Precision Medicine.

Precision medicine in cancer treatment has gained momentum due to advances in genomics and the mechanisms of targeted therapies.

The value of precision medicine has been shown with the identification of the genetic causes of tumors that differ among patients. Applied to nephrology, precision medicine can offer an earlier look at the potential risk for kidney disease.

An increasing number of predictive biomarkers, along with deeper understanding of “-omics” like genomics and metabolomics, is pushing rheumatology closer to treatment using precision medicine, according to a recent presentation.

Rush University Medical Center has taken precision oncology to a new level through an electronic health record module that incorporates genomic sequencing data into oncologists’ daily workflows.